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Abstract 
Background: Cardiotoxicity resulting in heart failure is a devastating complication of cancer 
therapy. A patient may survive cancer only to develop heart failure (HF) which is more 
deadly than cancer. 
Aim: This project aimed to describe the characteristics and outcomes of HF in patients with 
blood or breast cancer after chemotherapy treatment.  
Methods Queensland Cancer Registry, Death Registry and Hospital Administration records 
were linked (1996-2009). Patients were categorised as those with an index HF admission 
(that occurred after cancer diagnosis) and those without an index HF admission (non-HF). 
Results: 15,987 patients were included, 1,062 (6.6%) had an index HF admission. Median 
age of HF patients was 67 years (IQR 58-75) vs. 54 years (IQR 44-64) non-HF. More men 
than women developed HF (48.6% vs. 29.5%) and a greater proportion in the HF group had 
haematologic cancer (83.1%) compared with breast cancer (16.9%). After covariate 
adjustment, HF patients had increased mortality risk compared with non-HF patients (HR 
1.67 [95% CI, 1.54-1.81]), 47% of the index HF admission occurred within 1 year from 
cancer diagnosis; 70% within 3 years.  
Conclusion: Cancer treatment may place patients at a greater risk of developing HF. The 
onset of HF occurred soon after chemotherapy, and those who developed HF had a greater 
mortality risk.  
Keywords: Cardiotoxicity; Heart Failure; Chemotherapy; Cardiology; Oncology 
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Introduction 
Cardiotoxicity resulting in left ventricular failure is a potential outcome of cancer therapy. 
Patients may survive cancer only to develop heart failure (HF), which has a higher mortality 
rate than cancer.1 Current guidelines recommend that the development of cardiotoxicity 
should lead to reconsideration of further chemotherapy and thus limits cancer treatment 
options and potentially affect cancer outcomes.2 Treatment-induced cardiotoxicity is well 
established and may occur in one-third of cancer patients,1 although current figures are 
probably underestimates 3 as patients with underlying predisposition to cardiotoxicity are 
often excluded from cancer trials.4 Adult survivors of childhood cancers have been shown to 
have an eightfold risk of cardiac-related mortality.5 Cardiotoxicity, can occur up to 20 years 
after cancer therapy and maybe identified as a lifelong risk as new data emerges,3, 6 and may 
become more prevalent as survivorship from childhood cancer improves. 
The incidence of cardiotoxicity following chemotherapy varies based on the type of agent, 
with the cardiotoxicity incidence of anthracyclines between 1 and 26%, high-dose 
cyclophosphamide between 7 and 28%, trastuzumab between 2 and 28%, and tyrosine kinase 
inhibitors between 0.05 and 11%.1, 5 These drugs are commonly used to treat breast or 
haematologic cancers; therefore these cancers are the focus of this study. 
Treatment-related risk factors in cancer patients include specific chemotherapy agent(s) (with 
reversible and irreversible cardiotoxicity),1 dose exposure 7 and concomitant therapies 
(including anaesthetic procedures and radiation therapy).8, 9 In fact, treatment-induced 
cardiotoxicity should not be considered the result of a single treatment, but rather as the result 
of additive or supra-additive toxicities, in conjunction with risks such stress, history of 
cardiac disease, genetic profile, and body mass index.10 Cardiotoxicity is likely to become 
more prevalent as chemotherapy is administered to an ageing population. 
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Vigilant initial monitoring and early intervention during cancer treatment, with continued 
surveillance after treatment could prevent or ameliorate cardiotoxicity.1, 6, 10-14 A limited 
number of the possible risk factors associated with this toxicity (such as high cumulative 
doses of anthracyclines in the context of pre-existing heart disease) are well-understood.1, 5, 6, 
10-14 Before intervention studies are undertaken, the precise nature of the problem needs to be 
investigated.  
This study aimed to gain greater understanding of the development of HF in patients after 
exposure to chemotherapy for breast or haematologic (leukemias, lymphomas and related 
disorders) cancer. The focus of this paper is on the development of HF, acknowledging that 
other cardiovascular conditions may develop after cancer treatment.5 The objectives were to 
describe patient characteristics, duration of outset, mortality and survival between those who 
developed HF after chemotherapy compared to those who did not. The long term aim of this 
research is to better understand the profile of these patients so that appropriate inventions for 
prevention and potential reversal can be designed. 
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Materials and Methods 
Study design 
This study was a retrospective audit of linked health administration data from Queensland, 
Australia. The Queensland Cancer Registry (QCR), the Hospital Admitted Patient Data 
Collection and Birth, Deaths and Marriages from January 1996 to December 2009 were 
accessed. Approval was granted by the Metro South Health Service District Human Research 
Ethics Committee (HREC/11/QPAH/600). 
Participants 
Primary cancer diagnosis was used to identify the cancer site/morphology using the 
International Classification of Diseases and Tenth Revision Australian Modification (ICD 10-
AM) and ICD-O (oncology) site codes in the original linked dataset. Cancer sites were 
defined as breast (ICD 10-AM: C50) or haematologic (leukemias, lymphomas and related 
disorders) (ICD10-AM: C42, C77 and ICD-O: M9590/3-M9989/3) henceforth referred to as 
‘haematologic cancers’. 
Patients who did not undergo chemotherapy were excluded. Participants were categorised as: 
Those that had an index HF admission after cancer diagnosis (HF group) compared with 
those that did not (non-HF group). 
Variables 
QCR, Death Registry and Hospital Administration records were linked (1996-2009). Index 
HF must have occurred after the date of cancer registry entry. 
Demographic information was extracted from the QCR (Table 1). Age was categorised as 
<20 years, 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years and ≥70 years 
for the Cox proportional hazard modelling. Age groupings for the Kaplan-Meier survival 
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curve analysis were based on the median and were categorized as <50 years, 50–59 years, 
60–69 years and ≥70 years.  
Chemotherapy-receiving patients were identified from the relevant codes in hospital records, 
defined by ICD-9-CM (clinical modification) (99.25) and ICD-10-AM (Australian 
Modification) (96196-00, 96199-00, 96209-00, 96207-00, 96208-00, 96204-00, 13942-00, 
13915-00, 13918-00, 13921-00, 13927-00, 13939-00, 13942-00, Z51.1, Z51.2). 
Chemotherapy admissions were categorised as quintiles (Table 1). Details of radiotherapy 
treatment of patients were not included as data were not available for linkage. 
An index HF admission was defined as a patient’s first hospitalisation coded for HF. HF 
diagnosis was based on the ICD-9-CM (428.0. 428.1 and 428.9) and ICD-10-AM (I50.0, 
I50.1 and I50.9) codes. HF included Congestive HF, Left Ventricular failure and other 
unspecified cardiomyopathies.  
All-cause mortality data were extracted from the Queensland Birth, Deaths and Marriages 
database – a repository for all registered deaths in Queensland. Patients who died after the 
end of the study period (December 31 2009) were considered to be alive for the calculation of 
survival time and mortality.  
Data sources and data linkage  
The QCR has been collecting data since 1982 was used to identify patients with a primary 
diagnosis of breast or haematologic cancers. 15 
The QCR facility and Unit Record numbers were match-merged with Hospital Admitted 
Patient Data Collection episodes to identify those who had chemotherapy and those with an 
index HF admission following QCR registration. Details of pre-existing cardiovascular risk 
factors were not available in this administrative dataset. Death records were obtained from 
8 
 
Birth, Deaths and Marriages and were linked to QCR records. LinkageWiz software was used 
for probabilistic matching.16 
Bias 
To reduce false and mismatched linkages,17 a 20-step review process to identify false 
positives was undertaken within a broader quality control framework. The false positive rate 
for this methodology has been shown to be 0.3%.18 
Statistical methods 
Linked Health Data were extracted and coded using STATA 13.0 (STATA, Texas, USA) and 
analysed using IBM SPSS for Windows version 22.0 (IBM, Armonk, NY, USA). Differences 
in demographics, cancer treatment history and morphology/site were analysed for between-
group differences using Fisher’s exact test and chi-square. Where continuous data were non-
normally distributed, the data are presented as median (IQR) and compared using appropriate 
non-parametric tests. Differences were considered significant at p≤0.05. 
Standardized mortality ratios (SMRs) for all-cause mortality were derived using an indirect 
standardization methodology by calculating the age-specific, all-cause death rates of the 
Australian population for each year within the study period (1996–2009) relative to observed 
deaths in our study population. Data are presented as the mean of the yearly SMR 
calculations. 
Kaplan-Meier survival curves were derived to compare the time to death from cancer 
diagnosis between groups, and by sex and age using a log-rank test.  
Time-varying Cox proportional hazards regression models were used to evaluate factors 
associated with mortality risk during follow up within groups adjusted by demographic 
variables, cancer treatment history and morphology/site (Table 2). Hazard ratios (HR) were 
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used to describe the probability of survival after chemotherapy treatment. The proportional 
hazard assumptions and goodness of fit of the models were also tested.  
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Results 
Participants 
A total of 73,158 breast or haematologic cancer records were linked to hospital admissions 
and death records. Within the QCR there were 918 patients registered with multiple cancers 
(1 patient with four, 7 patients with three and 910 patients with two types of cancers). In 
order to count each patient once, the primary cancer diagnosis was selected and all other 
registrations were excluded (n=927). 
N=15,750 records were excluded that fell outside the study timeframe and 40,494 records 
were excluded as these patients did not receive chemotherapy. The final sample was 
n=15,987 patients, of these, n=1,062 had at least one index HF admission following their 
cancer diagnosis and n=14,925 had no HF admission. The Median follow up time was 3.34 
years (IQR, 1.34-7.25, range: 0-13.9 years) (Figure 1). 
Demographics and clinical characteristics 
The Median age at cancer diagnosis was 55.0 years (IQR, 44–65). 5.3% (n=852) were aged 
≤20 years and 34.8% (n=5,564) were aged over 60 years. There was a greater proportion of 
females (69.3%, n=11,074) than males (30.7%, n= 4,913). 52.2% (n=8,339) had a primary 
diagnosis of haematologic cancer and 47.8% (n=7,648) had a primary diagnosis of breast 
cancer. The overall SMR for the sample was 5.08 – a fivefold greater mortality rate than the 
Australian population. 
Compared to the non-HF group, HF patients were significantly older (p<0.001), there were a 
lower    proportion of female patients (p<0.001) and a greater proportion of patients with 
haematologic cancers (p<0.001) (Table 1). There were differences in the number of 
chemotherapy admissions between groups (p<0.001). Non-HF patients were more likely to be 
Australian-born and in a Married/De Facto relationship (Table 1). 
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Outcome data 
All-cause mortality was 2.45 times higher in HF than in non-HF patients (p<0.001), and HF-
related mortality was 5.80 times higher in the HF group compared to the non-HF group 
(p<0.001). SMR for all-cause mortality for the non-HF and HF groups were 5.27 and 4.19 
times greater than the comparable Australian population respectively, most likely due to the 
age differences between these groups. 
In the first 12 months after cancer diagnosis 47.1% of patients developed HF and 69.6% of 
patients developed HF within the first three years (Figure 2). All-cause mortality (adjusted for 
age, sex, marital status, country of birth, cancer site and chemotherapy admissions) differed 
between groups with the HF group having a greater risk of mortality relative to the non-HF 
group (HR 1.67 (95% CI, 1.54–1.81), p<0.001) (Figure 3).  
Mean survival times from cancer diagnosis were 9.57 years (95% CI 9.46-9.86, n=4166) and 
5.30 years (95% CI 4.99-5.62, n=728) for the non-HF and HF groups respectively. 
The time-varying Cox Proportional Hazard modelling showed non-HF patients had an 
increased risk of mortality with increasing age (Table 2). This was not observed in the HF 
patients with no difference in mortality with increasing age, excepting those aged over 70 
years (Table 2). Males had a higher and similar risk of mortality in both the HF and non-HF 
groups compared with females. Patients who were not Married/De Facto had increased risk of 
mortality in the non-HF group, but no difference was evident in the HF group. Patients born 
in a country other than Australia had a lower risk of mortality among HF patients and there 
was a higher risk of mortality in haematologic cancers relative to breast cancer in both 
groups.  
In the non-HF group relative to those who had 1–3 chemotherapy admissions, there was a 
decrease in mortality risk for each quintile of chemotherapy admissions, until ≥17 admissions 
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where there was a small but significant increase in mortality risk. However, there were no 
significant differences in mortality risk across quintiles of chemotherapy admissions in the 
HF group (Table 2). 
Kaplan-Meier survival curves of all-cause mortality by age, and sex in HF patients indicate 
similar survival rates between the younger patients (<50 years compared to 50–59 years); 
however, there was a steeper decline in mortality in older age-groups (log-rank p<0.001) 
(Figure 4). Survival rates were higher in female patients than in males (log-rank p<0.001). 
Discussion 
In the context of well-established evidence for causality between chemotherapy, radiotherapy 
and cardiotoxicity, this study aimed to determine differences in characteristics and clinical 
outcomes of cancer patients who received chemotherapy that has the highest incidence of 
cardiotoxicity and who subsequently developed HF relative to those who did not. We have 
shown that 6.6% of breast or haematologic cancer patients who received chemotherapy 
subsequently developed HF. Results from the USA,19 Australia 8, 20 and Europe 21 have 
shown HF rates ranging from 1.3-4% of the population. Our study suggests that cancer 
treatment could increase the risk of developing HF by approximately 2-3 times. 
In the HF group, 47.7% of patients had an index HF admission within 12 months following 
cancer diagnosis and 69.6% within three years. This is of concern, especially for patients who 
develop HF prior to the completion of chemotherapy, which may necessitate treatment 
termination and influence cancer-specific outcomes.  
The median age of HF patients was 67 years compared with 54 years in non-HF patients. In 
other studies of adults with HF, the median age of HF diagnosis has ranged from 70 to 82.5 
years.19, 21-23 Our results suggest that cancer treatment might trigger the development of HF at 
an earlier age than typically observed.  
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In the HF group there were a greater proportion of patients with haematologic cancers 
relative to those with breast cancer, compared to the non-HF group. This may be due to 
different drug exposure, older age of patients with haematologic cancers, and additional 
treatments including radiotherapy.  
During the study period the median number of hospitalisations (HF and chemotherapy 
admissions combined) and chemotherapy admissions were greater in the non-HF group. It is 
possible that the treatments were altered or prematurely ceased in some patients at the time of 
diagnosis of HF. This is supported by our observation that a high proportion of patients 
developed HF rapidly thereby resulting in fewer chemotherapy admissions. Furthermore, the 
number of hospitalisations and chemotherapy admissions may be less in the HF group due to 
the greater mortality of this population. 
Survival time was lower in the HF group compared to the non-HF group, with the 
combination of cancer and HF being 67% more deadly than cancer alone (Figure 3). This 
maybe expected as other studies have shown patients with HF having poorer prognosis 
compared to most solid-organ cancers.24  
In the HF group, all-cause mortality was 2.45 times greater than the non-HF group. Relative 
to the Australian population, those in the HF group had a fourfold higher mortality. Those in 
the non-HF group had a fivefold higher mortality than the overall Australian population. This 
is likely due to the age differences between groups with the SMR calculated for the non-HF 
group relative to a younger population. 
In non-HF patients, increases in mortality were observed with increasing age. This was not 
observed in HF patients, with no differences in mortality between older and younger patients, 
suggesting that the increased risk of mortality with HF overrides the effect of age alone. 
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Other studies have shown median survival times after HF diagnosis ranging from 3.21 years 
in women and 5.39 years in men.25 . 
The non-HF group also showed a decrease in mortality risk with increasing number of 
chemotherapy treatments, until ≥17, but there was no additional effect on mortality risk with 
increasing number of chemotherapy admissions in the HF group. This may be due to the 
moderation of chemotherapy cycles in the HF patients in accordance with the cardiotoxicity 
treatment guidelines.2 However, in the context of an observational study, there are numerous 
confounders that were unable to be considered.  
The difference in trajectory for patients with cardiotoxicity compared to those with cancer or 
HF alone has been presented schematically in Figure 5. 
Strengths and Limitations 
The strengths of this study are the large sample size and the inclusion of all cancer patients 
who underwent chemotherapy over a 14 year period. The ability to link administrative 
datasets allows for the integration of multiple databases to provide a comprehensive picture 
of patient outcomes.  
However, potential limitations should be considered, many of which are generic to this type 
of research. This study was one of the first from a newly established data linkage service, as 
such we could only access datasets that had custodian approval therefore we were unable to 
access information regarding cancer treatment including chemotherapy drugs, radiotherapy 
and pre-existing cardiovascular risk factors. Using the available data we included 
chemotherapy admissions as a surrogate for drug information and demonstrated differences 
in treatment regimes in patients who developed HF and those who did not.  
The inclusion of breast cancer patients has resulted in an over-representation of female 
patients. Also, our sample was not representative of the Queensland rural population. 
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Approximately 52% of the residential population lived in rural areas,26 however, in this study 
13.7% of patients lived in rural Queensland, it appears that metropolitan contact details were 
while undergoing treatment. Thus, residence was excluded from the Cox Proportional Hazard 
Models of mortality. 
With the inclusion of only HF hospitalisations and not other cardiovascular complications 
associated with cancer therapy, this study may be just the tip of the iceberg when describing 
the burden of cardiotoxicity on cancer patients. 
Clinical Implications  
This study showed that 69.9% of patients had an index HF admission within three years 
following cancer diagnosis; therefore monitoring should continue for a number of years 
following treatment. The European Society of Medical Oncology (ESMO) recommend that 
prior to undergoing chemotherapy, patients should be assessed for cardiovascular risk and 
vital signs should be monitored during chemotherapy infusion.27 For children, adolescents 
and young adults, the American Heart Association recommends monitoring patients to allow 
for early detection of potential cardiac conditions and timely intervention to prevent, reverse 
or slow deterioration and also tailoring cancer therapies to decrease risk of cardiotoxicity.28 
Given the emergence of new cancer treatments, we do not know how large the problem of 
cardiotoxicity associated with cancer treatment is likely to become. There are no accurate 
data to indicate the most likely stage of the cancer trajectory when HF develops, when 
intervention should begin, and how patients should be best-managed within the health system 
and in the community. Just as important, little has been published in regard to cancer 
survivors’ perceived cardiac health care needs and concerns, or whether they understand the 
risk of HF.  
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Conclusion 
Compared to HF in the non-cancer population after chemotherapy this group developed HF 
more rapidly (47% within one year and 69% in three years) at a younger age (67 years 
compared to 70 to 82.5 years). However, in both our population and the non-cancer 
population the prevalence was higher in males. There was a greater mortality risk in those 
with breast or haematologic cancer and HF compared to breast or haematologic cancer alone. 
Further research to understand predictors of cardiac risk in cancer patients is needed to 
develop strategies for patient management and risk mitigation.   
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Tables 
Table 1: Demographics, Mortality, Hospitalization and Chemotherapy Rates for all 
chemotherapy receiving breast cancer and haematologic (Leukemias, Lymphomas and related 
disorders) cancer patients 
Characteristics Heart Failure 
N=1,062 (6.6%) 
Non-Heart Failure 
N=14,925 (93.4%) 
P-value 
 
Age (at cancer diagnosis), years 
Median (IQR) 
67.0 (58 – 75) 54.0 (44 – 64) <0.001* 
Age Group, years, n(%) 
   < 20  
20–29  
30–39  
40–49  
50–59  
60–69  
   ≥ 70  
 
32 (3.0) 
14 (1.3) 
23 (2.2) 
71 (6.7) 
166 (15.6) 
322 (30.3) 
434 (40.9) 
 
820 (5.5) 
470 (3.1) 
1,359 (9.1) 
3,199 (21.4) 
3,926 (26.3) 
3,054 (20.5) 
2,097 (14.1) 
 
<0.001* 
 
Sex, n(%) 
Female 
Male 
 
546 (51.4) 
516 (48.6) 
 
10,528 (70.5) 
4,397 (29.5) 
 
<0.001* 
 
Marital Status, n(%) 
Married/De Facto 
Single/divorced/widowed 
 
635 (59.8) 
427 (40.2) 
 
9,719 (65.1) 
5,206 (34.9) 
 
0.001* 
 
Country of Birth, n(%) 
Australia 
All Other Countries 
 
759 (71.5) 
303 (28.5) 
 
11,221 (75.2) 
3,704 (24.8) 
 
0.007* 
 
Indigenous Status, n(%)  
Indigenous 
Non-Indigenous 
 
15 (1.4) 
1,047 (98.6) 
 
233 (1.6) 
14,692 (98.4) 
 
0.784 
 
Residence (Postcode), n(%) 
Metropolitan 
Rural/Remote 
 
916 (86.3) 
146 (13.7) 
 
12,954 (86.8) 
1,971 (13.2) 
 
0.609 
 
Cancer Morphology/Site, n(%) 
Breast 
Hematologic  
 
180 (16.9) 
882 (83.1) 
 
7,468 (50.0) 
7,457 (50.0) 
 
<0.001* 
 
All-cause Mortality  
Crude 
SMR 
 
728 (68.5) 
4.19 
 
4,166 (27.9) 
5.27 
 
<0.001* 
 
HF Related Mortality  
Crude 
 
279 (17.4) 
 
455 (3.0) 
 
<0.001* 
 
No of hospitalizations, Median 
(IQR) 
7 (3 – 15) 8 (4 – 15) 0.100 
No of chemotherapy admissions, 
Median (IQR) 
5 (2 – 12) 7 (4 – 14) <0.001* 
No of chemotherapy admissions, 
quintiles 
   
 1–3  392 (36.9) 3,067 (20.6) <0.001* 
 4–6 213 (20.1) 4,040 (27.1)  
 7–9 125 (11.8) 1,941 (13.0)  
 10–16 179 (16.9) 3,050 (20.4)  
 ≥ 17 153 (14.4) 2,827 (18.9)  
IQR indicates interquartile range (25th–75th percentile); and SMR, standardized mortality ratio 
Hematologic cancer= leukemias, lymphomas and related disorders 
Hospitalisations are a combination of admissions for HF and for chemotherapy 
* Significantly different at p≤0.05   
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Table 2: Adjusted time-varying Cox Proportional Hazard Models for all-Cause mortality 
between HF and non-HF. Data were adjusted for age, sex, marital status, country of birth, 
cancer site and number of chemotherapy admissions. 
 
 
  
 HF Patients Non-HF Patients 
Parameter HR (95% CI) P-value HR (95% CI) P-value 
Age, years 
Referent  Referent 
 
 < 20  
 20–29  1.98 (0.93-4.25) 0.078 1.83 (1.39-2.42) < 0.001* 
 30–39  1.67 (0.81-3.45) 0.168 2.61 (2.09-3.27) < 0.001* 
 40–49  1.35 (0.75-2.41) 0.314 2.99 (2.43-3.68) < 0.001* 
 50–59  1.39 (0.81-2.37) 0.228 3.39 (2.77-4.15) < 0.001* 
 60–69  1.64 (0.98-2.75) 0.062 4.75 (3.89-5.80) < 0.001* 
 ≥ 70  2.08 (1.25-3.47) 0.005* 8.71 (7.15-10.62) < 0.001* 
Sex     
Female vs Male 1.32 (1.11-1.55) 0.001* 1.26 (1.16–1.37) < 0.001* 
Marital status      
Married/de facto vs All other 1.16 (0.99-1.36) 0.073 1.18 (1.10–1.26) < 0.001* 
Country of birth     
All other vs Australia 0.77 (0.65-0.91) 0.002* 0.99 (0.93–1.06)      0.823 
Cancer site     
Breast Cancer vs haematologic  1.41 (1.12-1.77) 0.003* 1.29 (1.18-1.40) < 0.001* 
Number of Chemotherapy  
admissions 
    
 1–3  Referent  Referent  
 4–6 0.99 (0.94-1.04) 0.711 0.87 (0.85-0.90) < 0.001* 
 7–9 1.00 (0.95-1.06) 0.953 0.93 (0.90-0.96) < 0.001* 
 10–16 0.99 (0.94-1.04) 0.640 0.93 (0.91-0.96) < 0.001* 
 ≥ 17 0.99 (0.93-1.04) 0.604 1.04 (1.02-1.06) 0.001* 
HF indicates heart failure; HR, hazard ratio; and CI, confidence interval. 
Hematologic cancer= leukemias, lymphomas and related disorders 
* Statistically significant at p≤0.05 
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Figures 
Figure 1: Population selection flow diagram. This diagram displays the initial study 
population through to the final study population (exclusions included). 
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Figure 2. Time from cancer diagnosis to the first index heart failure admission in n=1062 
patients who underwent chemotherapy treatment for breast or haematologic (leukemias, 
lymphomas and related disorders) cancer 
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Figure 3: Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving cancer patients, adjusted by age, sex, marital status, 
country of birth, cancer site and number of chemotherapy admissions.  
  
 
 
 
 
 Year 
 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Numbers at risk               
Non-HF 14925 12368 9892 8025 6759 5750 4882 4048 3284 2580 1957 1395 786 388 
HF 1062 817 637 508 421 346 276 214 169 128 99 69 34 10 
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Figure 4. Probability of survival after treatment for cancer with chemotherapy in heart failure 
patients (unadjusted) by a) age, b) sex 
A) Age 
B)  Sex 
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Figure 5. The differential in patient trajectory of physical function declines to mortality for Cancer, 
Cardiotoxicity, Organ failure and Physical and Cognitive frailty. Adapted from (Murray and Sheik 
2008) 29 
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Figure Legends 
Figure 1: Population selection flow diagram. This diagram displays the initial study 
population through to the final study population (exclusions included). 
Figure 2. Time from cancer diagnosis to the first index heart failure admission in n=1062 
patients who underwent chemotherapy treatment for breast or haematologic (leukemias, 
lymphomas and related disorders) cancer 
Figure 3: Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving 
cancer patients, adjusted by age, sex, marital status, country of birth, cancer site and number 
of chemotherapy admissions.  
Figure 4. Probability of survival after treatment for cancer with chemotherapy in heart failure 
patients (unadjusted) by a) age, b) sex 
Figure 5. The differential in patient trajectory of physical function declines to mortality for 
Cancer, Cardiotoxicity, Organ failure and Physical and Cognitive frailty. Adapted from 
Murray and Sheik (2008) [31] 
 
 
 
